Brokerages Set Harrow, Inc. (NASDAQ:HROW) Price Target at $71.43

Harrow, Inc. (NASDAQ:HROW) has received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $71.4286.

A number of analysts have recently commented on the company. LADENBURG THALM/SH SH lifted their target price on Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Cantor Fitzgerald restated an “overweight” rating and set a $94.00 price target on shares of Harrow in a research note on Tuesday, November 11th. HC Wainwright lifted their price target on Harrow from $64.00 to $69.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. BTIG Research reissued a “buy” rating and issued a $63.00 price objective on shares of Harrow in a report on Wednesday, September 24th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Wednesday, October 8th.

Institutional Trading of Harrow

A number of institutional investors have recently modified their holdings of HROW. Teacher Retirement System of Texas grew its holdings in Harrow by 4.1% during the second quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company’s stock worth $259,000 after acquiring an additional 332 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Harrow by 2.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after purchasing an additional 341 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Harrow by 1.7% during the 3rd quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock worth $1,422,000 after purchasing an additional 500 shares in the last quarter. Pale Fire Capital SE grew its stake in shares of Harrow by 6.8% during the 2nd quarter. Pale Fire Capital SE now owns 8,683 shares of the company’s stock worth $265,000 after purchasing an additional 550 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Harrow by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock valued at $483,000 after purchasing an additional 790 shares in the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Stock Down 2.0%

Shares of NASDAQ:HROW opened at $49.00 on Monday. The company has a market capitalization of $1.81 billion, a PE ratio of -489.95 and a beta of 0.07. The company has a current ratio of 2.72, a quick ratio of 2.52 and a debt-to-equity ratio of 5.21. Harrow has a twelve month low of $20.85 and a twelve month high of $51.53. The firm has a 50 day simple moving average of $42.34 and a 200-day simple moving average of $39.18.

Harrow (NASDAQ:HROW) last posted its earnings results on Monday, November 10th. The company reported $0.33 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.11. Harrow had a negative net margin of 1.99% and a positive return on equity of 28.71%. The firm had revenue of $71.64 million for the quarter, compared to the consensus estimate of $73.70 million. On average, equities analysts predict that Harrow will post -0.53 EPS for the current fiscal year.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.